Snap Chart

Weight-Loss Drugs Aren't Just Changing Waistlines

A Bain survey shows GLP-1 drugs, like those known as Ozempic or Wegovy, lead to significant changes in consumer behavior that often persist even after consumers stop taking them.

By Emily Miller, Sarah Hershey, and Samantha Gorang

  • First published on dezembro 16, 2024

Snap Chart

Weight-Loss Drugs Aren't Just Changing Waistlines
en

About the Research

Data powered by Dynata, a leading global first-party data and insights platform.

Industry Expertise

Explore Bain's expertise in Consumer Products and learn how we can help your company.

LEARN MORE
Grocery store interior with shoppers, a produce island, stocked shelves, and a refrigerated dairy section
Tags

How We've Helped Clients

A Strategic Separation Enables New Growth for GSK and Haleon

See more related case studies

Designing a Sales Compensation Plan Based on an Unusual Metric

See more related case studies

Focus on core delivers growth for retailer

See more related case studies

Quer saber mais?

Ajudamos líderes do mundo todo a lidar com desafios e oportunidades cruciais para suas organizações. Juntos, criamos mudanças e resultados duradouros.